Entecavir for children and adults with chronic hepatitis B

Jing Wu; Shitong Xie; Yanfang Ma; Xiaoning He; Xinyue Dong; Qianling Shi; Qiangqiang Guo; Qi Wang; Meixuan Li; Naijuan Yao; Liang Yao

doi:10.1002/14651858.CD015536

Entecavir for children and adults with chronic hepatitis B

Jing Wu^*, Shitong Xie, Yanfang Ma, Xiaoning He, Xinyue Dong, Qianling Shi, Qiangqiang Guo, Qi Wang, Meixuan Li, Naijuan Yao, Liang Yao

^*Corresponding author for this work

Chinese Medicine - Clinical Division

Research output: Contribution to journal › Journal article › peer-review

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of entecavir versus no treatment or placebo for chronic hepatitis B infection in children and adults with chronic hepatitis B infection, who are either HBeAg-positive or HBeAg-negative.

Original language	English
Article number	CD015536
Number of pages	15
Journal	Cochrane Database of Systematic Reviews
Volume	2023
Issue number	2
DOIs	https://doi.org/10.1002/14651858.CD015536
Publication status	Published - 27 Feb 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/14651858.CD015536

Cite this

@article{6271c023c99940babd307225a585a960,

title = "Entecavir for children and adults with chronic hepatitis B",

abstract = "Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of entecavir versus no treatment or placebo for chronic hepatitis B infection in children and adults with chronic hepatitis B infection, who are either HBeAg-positive or HBeAg-negative.",

author = "Jing Wu and Shitong Xie and Yanfang Ma and Xiaoning He and Xinyue Dong and Qianling Shi and Qiangqiang Guo and Qi Wang and Meixuan Li and Naijuan Yao and Liang Yao",

note = "Publisher Copyright: {\textcopyright} 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.",

year = "2023",

month = feb,

day = "27",

doi = "10.1002/14651858.CD015536",

language = "English",

volume = "2023",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "John Wiley & Sons Ltd.",

number = "2",

}

TY - JOUR

T1 - Entecavir for children and adults with chronic hepatitis B

AU - Wu, Jing

AU - Xie, Shitong

AU - Ma, Yanfang

AU - He, Xiaoning

AU - Dong, Xinyue

AU - Shi, Qianling

AU - Guo, Qiangqiang

AU - Wang, Qi

AU - Li, Meixuan

AU - Yao, Naijuan

AU - Yao, Liang

PY - 2023/2/27

Y1 - 2023/2/27

N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of entecavir versus no treatment or placebo for chronic hepatitis B infection in children and adults with chronic hepatitis B infection, who are either HBeAg-positive or HBeAg-negative.

AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of entecavir versus no treatment or placebo for chronic hepatitis B infection in children and adults with chronic hepatitis B infection, who are either HBeAg-positive or HBeAg-negative.

UR - http://www.scopus.com/inward/record.url?scp=85150836617&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD015536

DO - 10.1002/14651858.CD015536

M3 - Journal article

AN - SCOPUS:85150836617

SN - 1465-1858

VL - 2023

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 2

M1 - CD015536

ER -

Entecavir for children and adults with chronic hepatitis B

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this